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ABSTRACT 
 
INTRODUCTION 
 
The cornerstone of treatment of acute coronary syndrome (ACS) is percutaneous coronary 
intervention (PCI) and dual antiplatelet therapy (DAT) with aspirin and the ADP-receptor 
inhibitor clopidogrel. However, some ACS patients will suffer from recurrent 
cardiovascular events, and it has been shown that this may partly be due to an insufficient 
antiplatelet response to DAT. In this thesis, we investigated platelet function in ACS.  
The overarching aim was to further investigate clopidogrel non-responsiveness with 
established and new methods to assess platelet function.  
 
 
METHODS AND RESULTS 
 
   In study I, we investigated if arterial and venous sampling give comparable results with 
respect to detection of poor antiplatelet responsiveness to clopidogrel and aspirin with the 
established method multiple electrode whole blood impedance aggregometry (MEA). 
Twenty-eight patients with coronary artery disease were investigated in connection to PCI. 
Identical number of patients with poor responsiveness to clopidogrel (7/28; i.e. 25 %) and 
aspirin (3/28; i.e. 11 %) were detected in arterial and venous blood samples with MEA. 
Thus, arterial and venous sampling can be used interchangeably in the detection of poor 
responsiveness to clopidogrel and aspirin when MEA is used to study platelet function. 
 
   In study II, we investigated ADP-induced platelet aggregation by MEA in 183 patients 
with ACS on DAT at discharge (3–5 days after admission). We also measured circulating 
microvesicles (MVs) and platelet derived MV (PMVs) in 154 of the ACS patients.  
Of note, MVs are small membrane buds released from various cells in response to 
activation or apoptosis. We found that around 20 % (36/183) of ACS patients were non-
responders (“high on-treatment platelet reactivity”; HPR) to clopidogrel. Flow cytometry 
measurements showed that circulating PMV levels were significantly higher in HPR 
compared to those with “sufficient” clopidogrel responsiveness (“normal on-treatment 
platelet reactivity”; NPR). Furthermore, in patients with strong inhibition to clopidogrel 
(low on-treatment platelet reactivity; LPR) PMV levels were significantly lower than in 
NPR patients. Thus, levels of circulating PMVs reflect platelet responsiveness to 
clopidogrel.   
 
   Study III was performed to elucidate if MVs from ACS patients on DAT influence 
platelet aggregation. Thus, we added MVs from samples of patients with ACS with HPR 
and from patients with Non-HPR (i.e, LPR or NPR) to clopidogrel, to platelet rich plasma 
obtained from healthy volunteers. Results showed that MVs from HPR patients 
significantly enhanced spontaneous platelet aggregation as compared to MVs from patients 
with Non-HPR. In addition, we could also show that MVs from ACS patients with diabetes 
and DAT, enhanced platelet aggregation compared to MVs from ACS patients on DAT 
without diabetes. MVs have the potential to enhance platelet aggregation, supporting the 
  
idea that MVs may not only be “markers” but also “makers” of physiological or 
pathophysiological processes.  
 
   In study IV, we investigated if circulating MVs expose a molecule of the humoral 
immune system pentraxin-3 (PTX3). Thus, we measured the presence of PTX3+-MVs in 
plasma in patients with acute myocardial infarction (AMI). We found that PTX3+-MVs 
were elevated at admittance in patients with acute ST-elevation myocardial infarction 
(STEMI; n=23) and that levels decreased after PCI. Further, the circulating PTX3+-MVs 
levels were even lower in AMI patients at discharge (3–5 days after admission; n=153),  
but not as low as in healthy subjects (n=15). Thus, PTX3 is exposed on circulating MVs  
in the acute setting of AMI, and the levels fall significantly over the days after the acute 
event. The PTX3+-MVs should be further phenotyped with our flow cytometry method  
to elucidate the origin of PTX3 and its possible role in acute coronary artery disease.  
 
 
CONCLUSION 
 
Clopidogrel non-responsiveness is present in every fourth to every fifth ACS patient on 
clopidogrel. This can be detected either in arterial or venous samples by MEA. The  
number of circulating MVs reflect platelet responsiveness to clopidogrel, and circulating 
MVs in ACS patients have the capacity to enhance platelet aggregation, indicating a 
possible functional role of circulating MVs in the setting of ACS. In acute AMI, MVs 
exposing PTX3 circulate in an elevated concentration. The role of these PTX3+-MVs 
deserves to be further investigated.      
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1   INTRODUCTION  
 
 
1.1  General background 
Coronary artery disease, the leading cause of morbidity and mortality in Sweden (1)  
and worldwide (2) is mainly caused by atherosclerosis, a progressive disease mediated  
by inflammation of the vessel wall causing endothelial dysfunction (3, 4). Upon progression 
of atherosclerosis focal lesions are formed – so called atherosclerotic plaques – which may 
cause luminal narrowing of the coronary arteries. When these plaques rupture high 
thrombogenic components from the core of the lesion are exposed to the blood. This leads 
to activation of platelets and other components of the coagulation system (5) resulting in the 
formation of a thrombus (6). When thrombosis occurs in a coronary artery, it may have the 
clinical presentation of an acute coronary syndrome (ACS).  
 
 
1.2  Acute coronary syndrome  
ACS is the umbrella term of the clinical signs and symptoms of myocardial ischemia. 
Depending on the location and severity of coronary thrombus formation, the clinical 
presentation can be ST-segment elevation myocardial infarction (STEMI) or  
non-ST-segment elevation myocardial infarction (NSTEMI). Although the clinical 
presentation may differ, both conditions are due to insufficient blood supply causing 
biochemically detectable cardiac myocyte injury and necrosis. In addition, unstable  
angina pectoris (UAP) is also included in the definition of ACS, but in contrast to  
STEMI or NSTEMI, there is no biochemically detectable sign of myocardial injury  
in UAP. 
 
The criteria of AMI are: 
 
v   Typical symptoms of ischemia, i.e. discomfort, pain or pressure in the chest 
New ischemia ECG changes (the occurrences of new ST-T changes or  
v   new right/left bundle branch block) 
v   Elevation of cardiobiomarkers (Troponin I or T), mandatory to establish the 
diagnosis. 
 
Nowadays, a very common treatment in ACS is percutaneous coronary intervention (PCI) 
with stent implantation, in combination with dual antiplatelet therapy (DAT) with aspirin 
and a P2Y12 inhibitor. DAT is needed both in the acute phase (to prevent acute coronary 
thrombus formation in connection to PCI) and as maintenance treatment to prevent 
recurrent thrombotic complications and death, especially to prevent so called stent 
thrombosis (when a thrombus is formed in stented areas of the coronaries).  
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However, despite DAT, there are some patients who suffer from major adverse cardiac 
events (MACE) including thrombotic complications within the first year (7, 8).   
One of the contributing factors for recurrent MACE in patients with prior ACS is platelet 
hyperactivity, despite ongoing DAT. This seems especially to be a problem among patients 
treated with the P2Y12 inhibitor clopidogrel (9-11). Notably, previous studies showed wide 
variability in platelet inhibiting responses to clopidogrel (12), and an association between 
insufficient responses to clopidogrel as assessed by point of care (POC) assays and 
increased risk for thrombotic events (13, 14). POC assays have therefore been in focus to 
detect high risk patients with a reduced response to DAT (15) as this may aid in the 
improvement in risk stratification, and lead to a more intense medical management and 
follow-up. 
 
 
1.3  Platelet function 
Platelets, or thrombocytes, are nucleus free “cells” with a diameter of about 2-4 µm.  
They are derived from megakaryocytes in the bone marrow and circulate when not 
activated in a discoid form, with a life span of 8-10 days until cleared from the blood  
by liver and spleen (16). In a healthy person, the platelet concentration in blood is around 
150-400 x 109 “cells”/L.  
The main physiological role of platelets is to maintain hemostasis, i.e. to prevent bleeding. 
However, platelets are also actively involved in other physiological or pathophysiological 
processes such as inflammation, angiogenesis, infection and cancer (17, 18). Apart from 
involvement in these processes, it is nowadays clear that platelets play a pivotal role in 
atherothrombosis and ACS.  
 
 
1.3.1   Platelet activation 
In a healthy person, platelet activation usually occurs in response to a vessel wall injury 
caused by e.g. trauma or a cut. In the ACS patient, however, the rupture of a preexisting 
atherosclerotic plaque is considered to be the general cause of profound platelet activation.  
In theory, the platelet activating factors may be similar in physiology and pathophysiology, 
including von Willebrand factor (vWF) and collagen exposed at the site of vessel damage. 
Notably, platelet activation is a multistep process involving tethering, adhesion, secretion 
and aggregation (19). In parallel, activation of the coagulation system with formation of 
thrombin – a very strong platelet agonist - takes place (20). 
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Figure 1: Schematic presentation of platelet activation and the effects of antiplatelet treatment:  
Platelets interact with compounds exposed following vessel wall injury, e.g. von Willebrand factor (vWF)  
and collagen, which result in platelet shape change and activation, and the release of various compounds  
from the platelets, such as adenosine diphosphate (ADP) and thromboxane A2 (TXA2). Following activation, 
the GPIIb/IIIa receptors cluster and increase their affinity towards fibrinogen. Platelet aggregation then occurs 
through the binding of fibrinogen to GP IIb/IIIa receptors on platelets, as shown in the figure above. The 
released platelet agonists further activate already activated platelet (amplification) and also activate other  
non-activated platelets in the vicinity of the injury. The actions of various antiplatelet drugs are also depicted 
in the figure above. 
 
 
The shape of platelets is changed during activation, from being discoid to irregular with 
protruding pseudopodia. This increases the surface of the platelets and facilitates the 
aggregation process. The membrane of the activated platelet also provides a surface where 
coagulation factors can accumulate and be activated, leading to thrombin generation and 
fibrin formation. Furthermore, the activated platelets release important platelet agonists 
such as ADP and thromboxane A2 (TXA2), as well as other compounds important for 
hemostasis, like fibrinogen and von Willebrand factor (21).  
 
In addition, activated platelets release the adhesion molecule P-selectin which is stored in 
a-granules and presented on the platelet membrane following degranulation. Membrane 
bound P-selectin may play a role both in the inflammatory and the hemostatic process,  
as it interacts with leukocytes, endothelial cells and also with other platelets (17).  
P-selectin molecules may also be shedded from the platelet membrane into plasma  
as “soluble P-selectin”.  
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As mentioned above, platelets contribute to inflammation, as they can expose and release 
various pro-inflammatory molecules including CD40 ligand (CD40L). In fact, platelets 
have been reported to be a main source of soluble CD40L (sCD40L) in the circulation (22). 
Another aspect of platelet activation is the release of microvesicles (MVs) into the 
circulation. This phenomenon is described in more detail below in section 1.4.  
 
 
1.3.2   Platelet receptors  
Platelets have numerous types of surface receptors including the integrins, which are 
important adhesion and signaling molecules. Notably, the GPIIb/IIIa receptor (see above)  
is an integrin and the most abundant platelet receptor, and is important in platelet 
aggregation. Other types of platelet receptors are the leucine rich repeat receptors of which 
the GPIb-IX-V-complex is the most abundant one, tetraspanins, selectins (e.g. P-selectin; 
see above), purinergic receptors (e.g. the P2Y12 receptor), and prostaglandin receptors 
(including the Thromboxane receptor). For a review of platelet receptors see e.g. (23, 24). 
 
 
1.3.3   Platelet inhibitors  
1.3.3.1 Aspirin 
 
Aspirin is without any doubt the most widely used antiplatelet agent. The “beneficial” 
antiplatelet effect of aspirin was described already in 1950 (25), and the mechanism  
through which aspirin exerts its antiplatelet effect was shown by John Vane in 1971 (26). 
Later on, numerous clinical trials have demonstrated the efficacy of aspirin in the treatment 
of CAD (27, 28).  
 
Aspirin (acetylsalicylic acid) acetylates a serine moiety in the COX-1 enzyme.  
By doing so, the substrate of COX-1, i.e. arachnoid acid (AA), is unable to reach the 
catalytic site of COX-1 and thereby the synthesis of thromboxane A2 is blocked, figure 1. 
Aspirin’s blockage of COX-1 is irreversible (26), meaning that the thromboxane production 
of the platelet is inhibited for the life span of the platelet. The inhibition of COX-1 in vivo 
occurs already at low doses, around 30 mg daily (29). However, present European guidelines 
recommend a maintenance dose of 75-100 mg daily for patients with CAD (30). 
 
Treatment failure seems to occur not only with clopidogrel (see below), but also with 
aspirin. The phenomenon “aspirin resistance” was reported by Helgason already in the 
1990s (31), and there have since then been numerous reports on this phenomenon, with a 
wide estimated prevalence between 1-60% (32, 33). Indeed, aspirin resistance has been 
reported to be associated with an increased risk of cardiovascular complications (34),  
but this observation has not been the focus of the present thesis, and is therefore not 
discussed in more depth here. 
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1.3.3.2  P2Y12 receptor inhibitors 
I. Ticlopidine 
 
Ticlopidine is the first generation of the thienopyridines, i.e. a class of oral drugs which 
irreversibly blocks the platelet P2Y12 receptor. Ticlopidine was introduced in France 
already around 1980 for the treatment and prevention of arterial thrombosis in coronary, 
cerebral and peripheral arteries. Due its severe side effects, i.e. bone marrow toxicity 
(leucopenia, thrombocytopenia, and pancytopenia), but also a bothersome diarrhea,  
newer thienopyridines have been developed (35, 36). 
 
 
II. Clopidogrel 
 
Clopidogrel is a second generation thienopyridine, figure 1, and was introduced in the  
clinic after the large CAPRIE trial published in 1996 (37). This drug is still one of the most 
used antiplatelet drugs for patients with CAD (38-40) and ischemic stroke (41). 
 
Clopidogrel is, like the other thienopyridines, a pro-drug which as such requires hepatic 
metabolism to generate active metabolites. The cytochrome P450 (CYP 450) enzyme 
system (mainly CYP2C19) metabolizes clopidogrel in a two-step process to generate a 
short-lived active metabolite which irreversibly bind to and block the P2Y12 receptor.  
Of the ingested dose only around 15% is metabolized to the active metabolite and the  
rest is excreted by kidneys as inactive metabolites, figure 2 (36, 42). 
 
The maximal inhibition of platelet aggregation is obtained within 2-6 h after clopidogrel 
administration (loading dose of 600 mg clopidogrel), and its offset of action, which 
coincides with the generation of new platelets, is between 5-10 days (38, 43). 
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Figure 2: Schematic presentation of the pharmacology of oral P2Y12 inhibitors. 
Ticagrelor is a direct-acting agent with reversible antiplatelet effects. In contrast, clopidogrel and prasugrel 
are irreversible P2Y12 inhibitors, and pro-drugs which are dependent on metabolization by the hepatic 
cytochrome P450 (CYP 450) system to generate active metabolites. This occurs in two steps for clopidogrel, 
and in one step for prasugrel (see above). The generation of active metabolites is less efficient for clopidogrel 
as compared to prasugrel (only 15% of the absorbed clopidogrel dose is converted to active metabolite).  
High-on-treatment platelet reactivity (HPR) for clopidogrel, which is considerably more common in 
clopidogrel than prasugrel or ticagrelor, is associated with several “clinical factors” such as acute coronary 
syndrome (ACS), diabetes mellitus (DM), chronic kidney disease (CKD), drug-drug interactions, and also 
genetic polymorphism of the hepatic CYP450 system.  
 
 
The protective effects of clopidogrel to cardiovascular complications have been shown in 
several large prospective CAD studies (37, 44, 45), but according to the literature 
approximately 20-30% of patients on clopidogrel show high on-treatment platelet 
reactivity (HPR) (46). There are several clinical factors known to be associated with 
clopidogrel HPR, such as genetic variation (CYP polymorphisms), drug-drug interactions 
(e.g. with proton pump inhibitors or statins), ACS, DM, CKD and obesity, figure (47-50). 
Notably, there is a strong association between the presence of HPR and development of 
MACE (13, 14, 51), and especially the risk for stent thrombosis in patients undergoing  
PCI (9, 52). Therefore, new and more effective antiplatelet agents (like prasugrel and 
ticagrelor) have been developed.  
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III. Prasugrel  
 
Prasugrel is the third generation of thienopyridines, figure 1, and was introduced in the 
clinic after the large TRITON study published in 2007 (53). Prasugrel was shown to be more 
effective in reducing the risk for recurrent thrombotic events compared to clopidogrel, but 
at the cost of increased risk of bothersome bleeding complications (53). As depicted in  
figure 2, prasugrel is dependent on the CYP 450 enzyme to form an active metabolite, and 
this occurs in a single-step oxidation process. Importantly, prasugrel has a faster onset of 
action (30 min- 4 h)(38, 43), and provide a stronger inhibition of ADP-induced platelet 
aggregation compared to clopidogrel, which likely explains the beneficial data on 
cardiovascular events observed in the TRITON study (53, 54). 
 
 
IV.Ticagrelor:  
 
Ticagrelor is an oral non-thienopyridine reversible P2Y12 antagonist, figure 1. Unlike 
clopidogrel and prasugrel, it is not a pro-drug and therefore it does not require metabolic 
activation. Ticagrelor has a fast onset of action (around 30 min-4 h), and it is important to 
realize that the degree of inhibition afforded by the drug is dependent on its actual plasma 
concentration, figure 2. The half-life of ticagrelor is 8-12 hours, and the offset of the drug is 
faster than for the thienopyridines (3-5 days until eliminated) (46). The pivotal PLATO, 
published in 2009, clearly showed reduced MACE in patients with ACS patients treated 
with ticagrelor compared to clopidogrel (55).         
                                                                                                                                                                                                                                                                                                                                                                                                                                                    
As expected (being a more potent platelet inhibitor than clopidogrel), ticagrelor treatment 
was associated with a higher incidence of non- coronary artery bypass grafting (CABG)-
related bleedings (56). 
 
 
V. Cangrelor  
 
Cangrelor is a short-acting platelet P2Y12 inhibitor developed for intravenous use in acute 
situations. Inhibition of ADP-induced platelet aggregation is observed minutes after start of 
drug infusion. The plasma half-life of the drug is very short (3-6 minutes), and the platelet 
response to ADP is completely restored in less than one hour after termination of the 
infusion. Because of its pharmacology, with a very rapid onset and offset, the drug is an 
attractive treatment in connection to PCI, when immediate inhibition of platelet activation 
is needed. In clinical trials the periprocedural use of cangrelor in the PCI setting was 
associated with improved clinical outcome (57).  
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1.3.3.3  Glycoprotein IIb/IIIa receptor antagonists 
The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor mediates platelet aggregation through the 
binding of fibrinogen, figure 1. The GP IIb/IIIa inhibitors (GPIs), abciximab, eptifibatide 
and tirofiban, are very potent platelet inhibiting drugs, and developed for intravenous use 
only (58). GPIs are used in some high-risk PCI patients despite rather weak available 
evidence, e.g. in patients with angiographic evidence of large thrombus burden, and in 
those with thrombo-embolic complications during PCI, e.g. slow flow and no reflow after 
stenting (59, 60). Notably, the GPIs are associated with a high risk of bleeding, and combining 
GPIs with novel P2Y12 inhibitors (prasugrel and ticagrelor) does not result in any benefit in 
the outcomes of patients with ACS (61). 
 
 
1.3.4   Measurement of platelet function 
The interest in assessing platelet function has increased considerably during recent years. 
Clinical settings where measurements of platelet function are of potential value include e.g. 
monitoring of platelet responses to DAT, detection of bleeding disorders, and in the 
evaluation of platelet function pre-, per-, and postoperatively.  
 
Some of the more commonly used platelet function methods are:  
 
1.3.4.1 Light Transmission Aggregometry (LTA) 
 
LTA was originally described by Gustav Born in 1962 (62), and is still, by many, considered 
to be the gold standard platelet function test. Platelet rich plasma (PRP) is used in this test, 
and after adding a platelet agonist, e.g. ADP, into a cuvette with PRP, the platelets begin to 
aggregate and the light transmission through the plasma increases as platelets aggregate. A 
photocell in the aggregometer detects the change in light transmission which is proportional 
to platelet aggregation.  
LTA has some disadvantages, such as the need for centrifugation of the blood sample (to 
obtain PRP) and poor standardization between laboratories. The method is not optimal as a 
POC test (63). 
 
 
1.3.4.2 VerifyNow 
 
VerifyNow is an automated POC test that measures platelet aggregation in anticoagulated 
whole blood. The test is carried out using commercially available cartridges with different 
agonists, like AA, ADP and TRAP. Briefly, platelets are stimulated by an agonist, and upon 
activation platelets bind to fibrinogen-coated beads in the cartridges which in turn leads to 
an increase in light transmittance. Data are registered as platelet reactivity units (PRU) (64). 
VerifyNow has been widely used to monitor platelet responses to DAT (65).   
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1.3.4.3 Multiplate 
 
Multiplate (66) is the POC test used in the present thesis. It is a whole blood impedance 
aggregometry device (67), which has been commercially refined, and equipped with two 
pairs of electrodes per test channel; a principle by the developer called multiple electrode 
aggregometry,(66). This construction provides improved quality control for each sample, 
figures 3 and 4. Indeed, the main weakness of the older versions of whole blood impedance 
aggregometers was the single pair of electrodes used (and reused) and their “between-
electrode” variability.  
 
The MEA device has five channels for parallel tests, figures 3 and 4, and can detect patients 
with HPR on DAT following PCI (9). 
 
 
 
 
 
 
 
Figure 3: Multiplate® analyzer (left), and its test cell with duplicate sensor electrodes and magnetic 
stirrer (right).  
The test measures the change in impedance between two electrodes when activated platelets adhere and 
aggregate to the surface of the electrodes. The change in impedance is registered as two aggregation curves 
per channel on the screen of the apparatus; platelet aggregation is expressed as the area under the curve 
(AUC), figure 4(66) . Adapted with permission of Roche Diagnostics Scandinavia AB. 
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Figure 4: Platelet aggregation curves obtained by multiple electrode aggregometry (MEA).  
High platelet response to ADP, AA and TRAP in a patient with STEMI (panel A). Antiplatelet effects 
afforded by DAT in a patient with NSTEMI (panel B).  
 
 
1.3.4.4 Flow cytometry 
 
Flow cytometry (FCM) is a rapid method for assessment of platelet function. Briefly, cells 
or vesicles are labeled with fluorescently labeled antibodies against desired proteins or 
markers. In the flow cytometer, cells pass through a flow chamber with a laser beam where 
the size (forward scatter) and complexity or granularity (side scatter) is registered by 
detectors. Moreover, the emitted fluorescence (i.e. positivity for labeled antibodies) is also 
detected by specific fluorescence detectors. (68). Platelet activation measurements by FCM 
can be performed in whole blood, platelet rich plasma or in washed platelets (69).  
 
FCM has been used for diagnosis of bleedings disorders, for assessment of platelet  
function (69), and also for monitoring of DAT (70). FCM is also used for measurement of 
MVs (71-73), which is described in more detail below, in section 1.4. 
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1.4   Microvesicles 
Microvesicles (MVs) are plasma membrane vesicles, ranging from 0.1 to 1.0 µm in 
diameter, released from cells in response to cellular activation or apoptosis, figure 5 (74). 
The phenomenon of MV formation was initially described in platelet preparations as 
“platelet dust” already in 1967 (75), but later on it has become clear that many cell types can 
release MVs including megakaryocytes, endothelial cells, erythrocytes and leukocytes.  
MVs are derived from the plasma membrane which under “resting conditions” consists of 
two layers of phospholipids. The inner layer is negatively charged as it harbours the 
negatively charged phospholipid phosphatidylserine (PS), figure 5. The normal structure 
and integrity of the cell membrane is maintained through activities of different enzymes in 
the membrane (including flippase, floppase and scramblase) (76). However, during cell 
activation, intracellular calcium levels are increased, and as a consequence of complex 
intracellular events blebs are formed from the cell membrane. In parallel with this, the 
activities of flippase, floppase and scramblase are influenced, and upon “blebbing” PS is 
“pushed” to the outer layer of the MVs formed and released from the cell. It has, however, 
become clear during recent years that not all MVs expose PS, as described in several 
studies, figure 5 (77-80). 
 
 
 
 
Figure 5: Schematic presentation of platelet microvesicle formation and release. 
Following platelet activation intracellular levels of calcium increase, and after a series of complex 
intracellular events MVs are formed and released from the platelet cell membrane. Beside exposing PS, 
platelet MVs may also expose e.g. tissue factor, P-selectin, and platelet specific receptors like GPIIb/IIIa, 
glycoprotein IX (CD42a) and glycoprotein Ib (CD42b).  
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Platelet MVs are reported as the most abundant MVs in the circulation; around 70-90%  
of all MVs in healthy subjects (81). MVs release may, according to the literature, be 
triggered by different conditions such as hypoxia,(82) cardiovascular stress (83), high fat 
consumption (84) and inflammation (85). Circulating MVs are thought to be removed from 
the circulation in the reticuloendothelial system (e.g. in the liver, spleen and lungs). The 
clearance rate in experimental studies in rodents varies between 5-50 min, and in 
exercising healthy humans MVs have been reported to be cleared within one hour after 
termination of exercise (86) .  
 
The exposure of PS on the membrane of MVs may enhance its elimination. Formation of 
MVs may be reduced by treatment with different drugs; such as P2Y12 receptor antagonists, 
GPIIb/IIIa inhibitors (GPIs) and statins (87, 88). 
 
The composition of the MV membrane, including lipids and proteins, is mainly determined 
by the parental cells, i.e. the cell from which the MV originated. Of note, MV may pick up 
and carry various molecules including different cytokines, viruses, micro RNAs, DNA and 
mRNA (74). In this way, MVs have been ascribed to be important “vectors” of 
pathophysiological processes like infections, atherosclerosis and cancer. The role of MVs in 
thrombotic disorders have been in focus of several investigations, and studies have 
suggested that the pro-coagulant effect of MVs may be due to exposure of PS and other 
pro-coagulant factors including TF (77, 89). Of note, MVs from activated platelet may be 
50-100 fold more pro-coagulant than the surface of the platelets themselves (88). 
 
Several studies have reported higher levels of PMVs in patients with ACS, especially in 
patients with STEMI, and compared to patients with stable CAD or healthy controls (89-91). 
Previous reports have also suggested that MVs could be used as biomarkers to aid in the 
detection of high-risk individuals, or to be used in the assessment of antithrombotic 
therapies (92, 93).  
 
 
1.5   Pentraxin-3 
The view of the human immune system is that it consists of two different systems. The first 
one is the innate immune system, which is a quickly responding non-specific “first line” 
system (minutes – hours), and the second one is the adaptive immune system. This second 
system is antigen-specific, and responds to stimuli within days. This may lead to the 
development of an “immunologic memory” of the stimuli that elicited the response (94).  
Pentraxin-3 (PTX3) is a molecule belonging to a superfamily of soluble proteins – the 
pentraxins – and is a part of the humoral arm of the innate immune system (95, 96).  
 
The perhaps most “famous” of the pentraxins is C-reactive protein (CRP),  
an acute phase protein which has been in focus of intense research during the last two 
decades (97, 98).Whereas CRP belongs to the “short pentraxins” (molecular weight  
around 25 kDa), PTX3 is a “long pentraxin” with a molecular weight of 45 kDa (96, 99). 
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PTX3 was first identified in endothelial cells (100), but available data show that PTX3 is 
produced in many different cell types like neutrophils, macrophages, dendritic cells, 
fibroblasts and smooth muscle cells, and even cardiomyocytes seem to be able to produce 
PTX3 (100, 101).The production of PTX3 can be induced by different stimuli including 
cytokines like TNF-α, IL-1, IL-6, and the bacterial lipopolysaccharide, and perhaps also by 
cholesterol, figure 6 (102). Preformed PTX3 may be stored in granules of neutrophils and 
released acutely in various disease states (103, 104). 
 
PTX3 is a multifunctional protein and when released into the circulation it can bind to 
different ligands such as C1q and C3 in the complement system, but also to diverse 
pathogens such as bacteria, viruses and fungi, and thereby promote phagocytosis (94, 105). 
Notably, PTX3 may be both pro- and anti-inflammatory depending on the situation and 
local of action (99). For example, it has been shown that PTX3 can bind to “and block” the 
actions of P-selectin, and thereby potentially reduce the recruitment of leukocytes into areas 
of inflammation (106). 
 
 
 
 
Figure 6: Schematic presentation of PTX3 production and effects.  
PTX3 can be produced in and released from many cells including neutrophils, monocytes, endothelial cells, 
dendritic cells and smooth muscle cells in response to various stimuli. The molecule has multifunctional 
properties and may be involved in various processes like inflammation, atherosclerosis and angiogenesis. 
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PTX3 expression has been reported to be elevated in coronary plaques from patients  
with UAP compared to plaques from patients with stable disease (107, 108). The plasma 
concentration of circulating PTX3 peaks 6-8 h from onset symptoms onset in AMI  
patients (101, 109, 110) (in some studies the plasma concentration increases from 1-2 ng/mL  
to 200-800 ng/mL) (94). Interestingly, an experimental study suggested that PXT3 may have 
a protective role in acute myocardial infarction through the regulation of the complement 
cascade (111). 
 
PTX3 has been suggested as a useful biomarker in the detection of ACS and has been 
postulated to be superior to CRP and troponin T (112). Furthermore, PTX3 has been reported 
to be positively associated with Killip class and negatively associated with left ventricular 
ejection fraction (113), and to be a predictor of 3-month mortality following AMI (110). 
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2   AIMS 
The overall aim of the present thesis was to assess platelet function in patients with ACS 
treated with clopidogrel, and its relation to markers of high risk for cardiovascular events 
such as inflammation and levels of circulating MVs. The specific aims were as follows: 
 
 
STUDY I 
 
To examine whether arterial and venous blood samples from patients with ACS, were 
comparable regarding platelet responsiveness to DAT by using MEA. 
 
 
STUDY II 
 
To investigate the possible association between platelet responsiveness to clopidogrel 
treatment and levels of circulating MVs and PMVs. 
 
 
STUDY III  
To measure the effect of circulating MVs obtained from patients with ACS on platelet 
aggregation, and the influence of the responsiveness to clopidogrel treatment 
 
 
STUDY IV 
 
To study the exposure of PTX3 on circulating MVs in patients with AMI.  
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3   MATERIAL AND METHODS 
3.1 Study population 
 
3.1.1 Paper I 
 
We compared the arterial to the venous blood samples for assessment of platelet 
aggregation with whole blood impedance aggregometry in 28 patients (5 females and 23 
males) with CAD. The patients were included between December 2009 and June 2010. 
ACS was defined as chest pain with a ST-T segment dynamic on ECG indicating an 
ischemic event or /and an increased level of cardiac biomarker (troponin I). The patients 
were pre-treated with oral loading of 500 mg aspirin and 600 mg clopidogrel unless they 
were on on-going continuous medication with these drugs. Coronary angiography was 
performed in all patients and 23 of them had PCI with stent implantation.   
 
 
3.1.2 Paper II 
 
We investigated the association between platelet reactivity and circulating MVs and PMVs 
in patients with ACS by including 200 consecutive patients with ACS between March 2009 
and February 2011. Nine patients were excluded due to their participation in other studies 
after the inclusion, 2 patients died before discharge and 6 patients with 3-vessel disease 
were accepted for CABG. The patients were pre-treated with oral loading of DAT as 
mentioned in study I. Coronary angiography was performed in all patients and the majority 
(n=166) had PCI with stent implantation. 
 
 
3.1.3 Paper III 
 
In this study, we assessed MVs-induced platelet activation in 30 patients with ACS, who 
were already included in study II. All the patients were pre-treated as mentioned in study I. 
All patients went through coronary angiography and PCI was performed in 25 out of them. 
Patients were divided in two groups based on antiplatelet effect of clopidogrel measured by 
MEA, i.e. those with high on-treatment platelet reactivity, HPR (AUC > 46 U; n=16) and 
those with low or normal on-treatment platelet reactivity, Non-HPR (AUC £ 46: n=14). 
Fresh isolated platelets were obtained from healthy volunteers (n=2) without any 
medication. 
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3.1.4 Paper IV 
 
In this study, we investigated the exposure of PTX3 on MVs in 179 patients with AMI. 
Patients were divided into two groups, acute STEMI group and discharge group. The 
STEMI group, with blood samples obtained in the acute phase, consisted of 23 patients and 
were included between June and December 2016. These patients were pre-treated with oral 
loading dose of 500 mg aspirin and 180 mg ticagrelor unless they were on on-going 
continuous medication with these drugs. The discharge group, with blood samples collected 
at discharge (3-5 days after admission), consisted of 57 STEMI patients and 99 patients 
with NSTEMI from the population in study II.   
Plasma samples were collected from 15 healthy volunteers with no history of 
cardiovascular or others chronic diseases were included as a control group. 
 
 
3.2 Blood collection 
 
3.2.1 Study I 
 
Both arterial and venous blood were obtained at the same time. For MEA analysis venous 
blood sample was collected in a 4.5-mL plastic vacutainer tube containing the direct 
thrombin inhibitor lepirudin (25 µg/mL, Refludan, Hirudin blood collection tubes),  
using 21-gauge needles. For arterial blood sample, after puncturing the radial (majority) or 
femoral artery and insertion of a 6-French arterial sheath, the arterial blood was collected 
through a plastic syringe and then gently filled into uncapped vacutatiner tubes, as 
mentioned above. 
 
 
3.2.2 Study II 
 
Blood samples were obtained at discharge (3-5 days after admission), or roughly two 
weeks after admission in those patients receiving Abciximab (n=57) during PCI.  
For MEA assessment the blood samples were obtained as described in study I. Blood 
samples for PMV measurement were collected into 5 mL vacutainer tubes  
containing 0.5 mL 0.129 M sodium citrate (Becton Dickinson [BD], Plymouth, UK)  
using 21-gauge needles (BD Vacutainer needles). The samples were then immediately 
centrifuged at 2000g for 20 minutes at room temperature (RT) to obtain platelet-poor 
plasma (PPP). Aliquots of 500 µL PPP were later dispensed into plastic tubes and frozen  
at -80 °C until analysis. 
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3.2.3 Study III 
 
Venous blood was obtained at discharge (3-5 days after admission) into 5 mL vacutainer 
tubes containing 0.5 mL 0.129 M sodium citrate. All the samples were immediately 
centrifuged at 2000g for 20 minutes at RT to obtain PPP. Aliquots of 500 µL PPP were 
later dispensed into plastic tubes and frozen at -80 °C until analysis. 
 
 
Platelet isolation:  
Fresh platelets were obtained from two healthy volunteers with no history of cardiovascular 
disease and with no medication. Venous blood was obtained into 5 mL vacutainer tubes 
containing 0.5 mL 0.129 M sodium citrate. After careful mixing, the samples were 
centrifuged at 190g for 10 minutes in RT, to obtain PRP. Roughly 2/3 of the PRP was 
collected for further analysis. To obtain platelet-free plasma (PFP), the remaining plasma 
was centrifuged once at 2000g for 20 min, in RT. The supernatant was collected and further 
centrifuged at 10 000g for 30 min, in RT.  
 
 
MP isolation: 
PPP was thawed in a water bath for approximately 5 minutes (37 °C) and then centrifuged 
at 2000g for 20 min at RT, in order to remove any debris or cells that may interfere with the 
analysis. The supernatant was then centrifuged at 20 800g for 45 minutes in RT. After 
centrifugation, the supernatant was discarded and equal amount of phosphate buffer 
solution was added to the pellet. The sample was again centrifuged at 20 800g for 45 
minutes in RT. Again, the supernatant was discarded and the remaining pellet was vortexed 
for roughly 30 seconds and later used in the analysis.  
 
 
3.2.4 Study IV 
 
Blood samples in the acute STEMI group were collected in the catheterization laboratory 
before primary PCI. After puncturing the radial artery blood was obtained from the arterial 
sheath inserted for angiography, and before contrast injection. Blood was drawn in a 
syringe and then immediately transferred into vacutainer tubes containing 0.129 M sodium 
citrate (Becton Dickinson [BD], Plymouth, UK) using 21-gauge needles (BD Vacutainer 
needles). In addition, samples were collected from an antecubital vein around 23 hours after 
PCI using 21-gauge needles (BD Vacutainer needles) and vacutainer tubes containing 0.129 
M sodium citrate. 
 
In the discharge group, blood samples were collected as described earlier in study II. 
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3.3 Methods 
3.3.1 Multiple electrode aggregometry  
Details of this method have been described above and previously (66) Briefly, after at  
least 30 minutes of incubation at RT, whole blood was diluted with NaCl solution (1:1)  
and incubated again in 37°C for 3 minutes. Platelet activation was induced by adding ADP 
(final conc. 6.4 µM) or AA (final conc. 0.5 mM) and aggregation was measured for 6 
minutes in duplicate (i.e. two channels for each agonist). Results are expressed as area 
under the curve (AUC: 1U = 10 AU*min). Cut-off values for MEA data presented herein 
were defined as an AA value of ³ 30 U as aspirin non-responders (114) and an ADP value of 
more than 46 U for HPR and 46 U or less for NPR to clopidogrel, as established by ROC 
analyses in other studies (115, 116). To assess the patients with a higher risk of bleeding we 
used cut-off values defined as an ADP value less than 19 U for low on-treatment platelet 
reactivity (LPR), and between 19 U to 46 U for NPR (14, 117). 
 
 
3.3.2 Flow cytometric measurement of MVs and PMVs  
The measurement of MVs and PMVs was performed by flow cytometry. Briefly, PPP was 
thawed and later centrifuged initially at 2000g for 20 minutes and re-centrifuged at 13 000g 
for 2 minutes at RT. Subsequently, the supernatant, which includes MVs, were incubated 
for 20 minutes in the dark with specific antibodies. In study II, MVs were labelled with 
phalloidin-Alexa 660 (Invitrogen, Paisley, UK), lactadherin-FITC (Haematologic 
Technologies, Vermont, USA) and CD42a-PE (GPIX, Beckman Coulter, Brea, CA, USA). 
In addition, CD154-APC (abcam, Cambridge, UK) and CD62P-APC (Beckman Coulter, 
Brea, CA, USA) were measured in the PMV population (PS+ CD42a). In study IV, MVs 
were labelled with anti-PTX3-PE (Novus Biologicals, LLC, Littelton, CO, USA). 
  
The MV gate was determined using Megamix beads (0.5, 0.9 and 3.0 µm beads, BioCytex, 
Marseille, France). MVs were defined as particles less than 1.0 µm in size, and positive for 
antibodies as described above. Conjugate isotype-matched immunoglobulin with no 
reactivity against human antigens was used as a negative control to define the background 
noise of the cytometric analysis. 
 
 
3.3.3   Assessment of PTX3 concentration by ELISA 
Plasma samples from 13 patients with acute STEMI and 15 healthy volunteers, were 
separated into 3 fractions; plasma, MV-free supernatant and MV-enriched pellet by  
high-speed centrifugation as described in section 3.2.3. Total concentrations of PTX3  
were measured in each fraction by a commercially available ELISA kit (R&D Systems, 
McKinley Place NE, Minneapolis, USA) according to the manufacturer’s instruction.   
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3.3.4 Assessment of platelet aggregation in 96-well microplate 
 
Assessment of platelet aggregation by using a 96-well microplate is ealier described 
elsewhere by Armstrong et al. (118). In study III, this method was modified in order to use 
MVs as agonists. Briefly, 100 µl PRP from healthy individuals, was added to the wells of a 
96-well plates (Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA), in triplicates. 
MV-enriched pellet (50 µL) from patients, was then added to the wells, in triplicates as well. 
As a positive control, 10 µM of ADP (F. Hoffmann-La Roche Ltd., Basel, Switzerland) was 
added in wells containing PRP (duplicates). Moreover, PRP and PFP without agonists, was 
used as negative control (0% aggregation) and positive control (100% aggregation). Plates 
were then placed in a 96-well plate reader (Tecan, SunriseÒ, Zurich, Switzerland) and 
absorbance determined at 595nm every 15s (with shaking) for 60 min at 37°C. Changes in 
absorbance were converted to % aggregation by reference to the mean absorbance of PRP 
and PFP in both healthy volunteers. Both peak aggregation (max % aggregation) and 
aggregation over time (area under the curve; AUC) was assessed as seen in, figure 7.  
 
 
                       
 
Figure 7: Microvesicle induced platelet aggregation.  
Changes in absorbance were converted to percent aggregation by reference to the absorbance of platelet rich 
plasma (PRP) and platelet free plasma (PEP). Data presented as both peak aggregation and aggregation over 
time (area under the curve, AUC). 
 
 
 
 
 
 
  21 
3.4 Statistical analyses 
Statistical analyses were performed using SPSS software, version 22, 23 and 25 (IBM, 
Armonk, NY). To assess the normal distribution of the data, both visually histogram and 
also the Shapiro-Wilks test were used. Continuous variables are expressed as mean ± SD 
for normally distributed data, and median values with lower, upper quartiles for non-normal 
distributed data. Comparisons of continuous variables within groups were performed by 
independent t-tests for normally distributed data and for non-normally distributed variables 
Mann-Whitney U-test was used. Pearson´s or Spearman´s correlation coefficients were 
used, depending on normally and non-normally distributed data, for estimation of 
correlations between variables. For all statistical tests and confidence intervals, two-sided 
tests were used and a p-value of <0.05 was considered statistically significant. 
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4 RESULTS  
 
4.1 Study I 
Platelet aggregation in both arterial and venous blood samples was measured by MEA and 
was expressed as the AUC. The result showed a significant correlation between platelet 
aggregation in both arterial and venous blood by use of AA and ADP-induced aggregation. 
The correlation coefficients (R2) were 0.96 (p<0.0001) and 0.95 (p<0.0001) respectively, 
figure 8.  
 
 
 
Figure 8: Correlations between platelet aggregation measured as the area under the curve (AUC) in 
samples collected from arterial (x-axis) and venous blood samples (y-axis).  
The left panel (A) shows adenosine diphosphate (ADP) induced aggregation (n=28) and the right panel (B) 
shows arachidonic acid (AA) induced aggregation (n=28). Correlation coefficients (Spearman’s rank 
correlation coefficient) and p-values are shown. Adaped with permission from Scandinavian Journal of 
Clinical and Laboratory Investigation.(119) 
 
 
We also demonstrated that platelet aggregation, expressed as AUC, for both AA- and ADP-
induced aggreagtions, were simillar in arterial and venous blood. Patients were divided 
according to established cut-off values (117) in LPR (£188 AUC), NPR (189-467 AUC) and 
HPR (³468 AUC) based on the response to clopidogrel treatment. Cut-off values for AA-
response were defined as normal responders (<300 AUC) and low responders (³300 AUC) 
based on the response to aspirin treatment, figure 9 (114).  
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Figure 9: The left panel (A) shows the number of patients defined as low on-treatment platelet reactivity 
(<188 AUC), (agreement 92%, kappa 0.83), normal on-treatment platelet reactivity (189-467 AUC), 
(agreement 92%, kappa 0.85), and high on-treatment platelet reactivity (>468 AUC) to clopidogrel in arterial 
and venous blood samples. The right panel (B) shows the number of patients defined as normal responders 
(<300 AUC) and low responders (³300 AUC) to arachidonic acid (AA) induced aggregation. Adapted with 
permission from Scandinavian Journal of Clinical and Laboratory Investigation.(119) 
 
 
4.2 Study II 
 
4.2.1 Multiple electrode aggregometry 
 
ADP-induced platelet aggregation was analyzed, by MEA, from available blood samples 
in183 patients with ACS, treated with DAT (aspirin and clopidogrel). The data regarding 
ADP-response to clopidogrel were positively skewed. The median value of ADP-induced 
platelet aggregation at discharge (3-5 days after admission) was 22 U [3,5:103,5]. The 
results showed that 36 (20%) of these patients were with HPR, figure 10.  
 
We also assessed the antiplatelet effect of clopidogrel treatment on MVs in 154 patients. 
Using the cut-off values suggested by Sibbing et al.(117) 28 patients (18%) of these patients 
showed to be with HPR, 57 patients (37%) with NPR and 69 patients (45%) with LPR to 
clopidogrel. 
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Figure 10: Adenosine diphosphate (ADP) induced platelet aggregation units (U) in 183 ACS patients on 
clopidogrel.  
HPR: high on-treatment platelet reactivity. Adapted with permission from Platelets.(120) 
 
 
4.2.2 Microvesicles and platelet derived microvesicles 
 
MVs (MVs exposing PS, i.e. lactadherin positive) and PMVs (MVs expressing PS together 
with CD42a and CD62P (P-selectin) or CD154 (CD40 ligand) were analyzed by flow 
cytometry as described previously. Patients with HPR to clopidogrel had significantly 
higher number of MVs, PMVs and PMVs exposing CD62P compared to patients without 
HPR to clopidogrel (p<0.05 and p<0.01 respectively). However, no differences were 
observed CD154 expression between these two groups, figure 11.  
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Figure 11: Effect of clopidogrel on microvesicles (MVs) and platelet-derived microvesicles (PMVs) 
production in ACS patients.  
A value of >46 U was used to define high on-treatment platelet reactivity (HPR). *p<0.05, **p<0.01. Adapted 
with permission from Platelets.(120) 
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Furthermore, we sub-grouped the patients using three cut-off values according to  
Sibbing (117), i.e. LPR, NPR and HPR. Patients with LPR had significantly lower levels of 
PMVs compared to HPR patients to clopidogrel treatment, figure 12. 
 
 
 
Figure 12: Effect of clopidogrel on microvesicles (MVs) and platelet-derived microvesicles (PMVs) 
production in ACS.  
High on-treatment platelet reactivity (HPR). Normal on-treatment platelet reactivity (NPR). Low on-treatment 
platelet reactivity (LPR). A value of > 46 U was used to defined HPR, a value of 19–46 U as NPR and a value 
of < 19 as LPR. *p<0.05 and **p<0.01. Adapted with permission from Platelets (120). 
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4.3 Study III 
The mean age of the patients in HPR group was 66.9 ± 7.5 yeas and consisted of 4 women 
and 12 men. The median level of ADP response to clopidogrel in these patients was 77.5 
[56.0:81.3] U. 
The Non-HPR patients had a mean age of 69.6 ± 10.2 years and consisted of 14 men. The 
median level of ADP response to clopidogrel among these patients was 5.5[4.0:15.5] U. 
 
MVs from patients with HPR to clopidogrel, induced significantly higher platelet 
aggregation compared to MVs from Non-HPR patients to clopidogrel as measured as 
aggregation over time, figure 13 (panel A) and peak aggregation, figure 13 (panel B).  
 
Moreover, a significant correlation was found between concentrations of MVs and  
MV-induced platelet aggregation measured as both AUC and peak. Results showed 
significant correlations between MVs (PS+ MVs), CD42a+ MVs (platelet-MVs) and 
CD42a+ CD62P (platelet-derived MVs expressing P-selectin) and AUC,  
figure 14 (panel A-C).   
 
In a similar way, peak aggregation in PRP was correlated to PS positive MVs  
(r2=0.32, p=0.023), CD42a+ MVs (r2=0.39, p=0.021) and CD42a+ CD62P MVs  
(r2=0.33, p=0.016), but not to CD42a+ CD154+ MVs (r2=0.00, p=0.97). 
 
Patients with DM (n=9) had elevated platelet aggregation over time (AUC) and peak 
aggregation compared to patients without DM (n=21), figure 15 (panel A-B). The 
concentration of MVs in the DM patients did not correlate to MV-induced aggregation 
levels.  
 
 
 
 
Figure 13: Microvesicle induced platelet aggregation in patient with HPR and Non-HPR to clopidogrel 
treatment.  
The effect of MVs on platelet aggregation in HPR (n=16) and Non-HPR (n=14) patients, presented as area 
under curve (AUC), panel A, and peak aggregation, panel B. Data are presented as box plots (median and 
min-max values). Differences in AUC and peak aggregation between groups, was calculated with  
Mann-Whitney U-test.  
A B
P=0.0039P=0.0091
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Figure 14: Correlation between MV concentration and MV activity measured as max levels of platelet 
aggregation over time (AUC).  
MVs assessed by flow cytometry and phenotyped as phosphatidylserine expressing MVs (panel A), platelet 
derived MVs (panel B) and platelet derived MVs expressing CD62P (panel C). Data shows all patients 
(n=26), i.e. both HPR and Non-HPR. Spearman’s rank correlation coefficient was used and both correlation 
coefficients and p-values are shown. 
 
 
 
 
Figure 15: MV-induced platelet aggregation in all patients (n=30) with and without diabetes mellitus. 
Data presented as aggregation over time (area under the cure; AUC), panel A, and peak aggregation, panel B. 
Data are reported as box plot (median and min-max values). Differences between groups (DM and Non-DM) 
were calculated with Mann-Whitney U-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
BA
r2 = 0.22
P = 0.031
r2 = 0.31
P = 0.021
r2 = 0.24
P = 0.018
C
A B
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4.4 Study IV 
The study population baseline clinical characteristics are shown in Table II. 
 
Table II: Baseline clinical characteristics of the study population.  
   
Subjects 
 
Variables 
 
Acute  
STEMI 
(n=23) 
 
Discharge 
Group 
(n=156) 
 
Healthy 
Controls 
(n=15)  
 
Age (years) 67.6 ± 11.5 65.0 ± 11,0 69.0 ± 5.7 
Females / Males  6 / 17 29 / 127 6 / 9 
Body mass index (kg/m2) 27 ± 4.2 27.3 ± 3.8 - 
Creatinine clearance (Cockcroft–Gault)  67,6 ± 14,8 90,9 ± 29,4 - 
Hypertension (%) 8 (34.8) 92 (61,3) - 
Diabetes mellitus (%) 5 (21.7) 35 (22,4) - 
Active smoking (%) 3 (13) 36 (23,1) - 
Previous CAD (%) 4 (17.4) 32(20,5) - 
Notes: Data are presented as mean ± standard deviation, numbers of patients and percentages. 
CAD: coronary artery disease; STEMI: ST-segment elevation myocardial infarction. 
 
 
4.4.1 Plasma levels of PTX3+-MVs assessed by flow cytometry  
 
The median level of PTX3+-MVs was significantly elevated in acute STEMI patients 
before PCI compared to approximately 23 hours after PCI, figure 16 (panel A).  
The levels of PTX3+-MVs in acute STEMI patients after PCI were also significantly higher 
compared to both patients at discharge and healthy controls, figure 16 (panel B). 
 
 
4.4.2 Assessment of soluble PTX3 and MV-bound PTX3 by ELISA 
 
To investigate the proportion of soluble and/or bound PTX3 in circulation, plasma samples 
were fractionated and measured with an PTX3 ELISA. 13 patients with acute STEMI with 
the highest PTX3+-MV levels measured by FCM were included, as well as 15 healthy 
control subjects. The results showed significantly elevated levels of PTX3 in plasma,  
MV-free supernatant and MV-enriched pellet in patients with acute STEMI compared to 
healthy subjects, figure 17. We observed a tendency to higher PTX3 levels in the MV-
enriched pellet in the patients, however the differences were not significant.   
 
  30 
 
 
Figure 16: Flow cytometric measurement of PTX3+-MVs.  
Levels of PTX3+-MVs in acute STEMI patients before PCI compared to approximately 23 hours after PCI, 
panel A. Levels of PTX3+-MVs in acute STEMI patients after PCI compared to patients at discharge (3–5 
days after admission) and to healthy controls, panel B. * p<0,05 and ** p<0,001. 
 
 
 
                              
 
Figure 17: ELISA assessment of PTX3 in plasma, MV-free supernatant and MV-enriched pellet. 
Patients with acute STEMI demonstrated elevated levels of PTX3 in both plasma, MV-free supernatant and 
MV-enriched pellet compared to healthy controls. ** p<0,001. 
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5   GENERAL DISCUSSION 
 
The overarching aim of this thesis has been to learn more about platelet function and MVs 
in ACS, and to further explore the efficiency of DAT with aspirin and clopidogrel. We 
focused on clopidogrel since this was the first choice among P2Y12 receptor inhibitors when 
the work with the thesis started.  
 
 
5.1 Study I 
 
When the work with this thesis started, we wanted to reduce the possibility that  
pre-analytical procedures influenced platelet function as assessed by MEA. More 
specifically, we wanted to be able to use both arterial and venous blood when assessing 
platelet responsiveness to DAT. Notably, blood sampled from the arterial side is easier to 
obtain in the acute and stressful phase of ACS in connection to PCI, as it may be obtained 
from the arterial sheath used for coronary angiography and PCI. On the other hand, venous 
blood is more easily obtained in “the everyday health-care setting” e.g. at discharge or 
during follow-up at the out-patient clinic.  
 
Our results showed no significant difference between arterial blood samples and venous 
ones in the detection of “non-responders” to aspirin or clopidogrel, as analyzed by MEA. If 
data obtained are scrutinized in more detail (e.g when presented as Bland-Altmann plots), 
measurements performed in arterial vs venous samples were not identical, but the 
agreement was acceptable. Some previous studies have reported, that there may be 
differences in test results in arterial and venous samples. Reasons for this may e.g. be a) 
increase in platelet aggregability in response to increased arterial shear stress; b) a higher 
oxygen content of arterial blood influencing platelet reactivity; c) exposure to synthetic 
surfaces of the long catheters used for arterial sampling (121-123). One study by Frumento et 
al suggested that it was the catheter length and lumen used to obtain blood samples rather 
than the oxygen content of blood that influenced test results the most.(122) However, it is 
important to consider that the sensitivity to pre-analytical handling may differ between 
different methods used to assess platelet function or other aspects of hemostasis. Thus, the 
study performed by Frumento used thrombelastography, which is a global hemostasis test 
rather than a specific platelet function test, and this method may be differently sensitive to 
sampling compared to other platelet function tests.  
 
Importantly, our results in study I, showing comparable results between arterial and venous 
samples, were later supported by a study performed by Lancé et al. They studied ADP- and 
AA induced platelet aggregation with MEA (124). Additionally, they also used PFA-100 and 
studied thrombin generation (calibrated automated thrombogram). Sampling was, however, 
not identical with our study, as the arterial samples were obtained from the radial artery 
with a 20 G catheterization set, and from three different venous locations/sampling 
techniques (central venous line, venous line, and venipuncture by a G18 needle). Data 
obtained with MEA were, however, comparable with the different sampling techniques, and 
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as reasoned by Lancé it is likely that MEA is less sensitive to pre-analytical procedures, 
compared to other techniques like FCM or thromboelastography. It should also be put 
forward that the use of a wide boar (6F) introducer in our study may cause a comparably 
low shear stress and thereby likely a lower tendency to cause platelet activation. In 
summary, it is important to assess if pre-analytical handling influences the methods used, 
especially if different sampling procedures are employed in the same study, and different 
methods may differ in their sensitivity to pre-analytical handling.   
 
 
5.2 Study II 
 
In study II we investigated the relationship between platelet reactivity and circulating MVs 
and PMVs in patients with ACS at discharge, i.e 3-5 days after admission, by using MEA. 
The main finding was that there was a relationship between clopidogrel responsiveness and 
circulating MVs, and circulating PMVs; the latter defined as MVs exposing both PS and 
CD42a. This association was also observed when dividing patients further, i.e as being 
high, normal or low clopidogrel responders (i.e having low-on treatment [LPR],  
normal-on-treatment [NPR] and high-on-treatment platelet reactivity [HPR], respectively). 
Thus, we could demonstrate a concentration gradient in CD42a and CD62P positive PMVs, 
showing that with decreasing responsiveness to clopidogrel treatment the number of 
circulating PMVs increased. These findings were further supported by positive correlations 
between ADP-induced aggregation and PMV counts (r2 0.26 and 0.22; p<0.0001 for both). 
  
To the best of our knowledge when published our study was the first to demonstrate an 
association between responsiveness to clopidogrel treatment and levels of circulating 
PMVs. An earlier study by Kalantzi and coworkers, showed lower PMV generation in vitro 
in PRP from ACS patients who were “clopidogrel responders” compared to those who were 
“non-responders” (125), thus in large supporting our findings but in an in vitro setting.  
Our interpretation is that in patients with a recent ACS and on aspirin, PMV formation in 
vivo can be reduced by clopidogrel, and our data are in agreement with a P2Y12-dependent 
PMV formation in vivo. The data also suggest that stronger P2Y12 inhibition would result 
in more efficient inhibition of PMV generation, but this should be studied in more detail in 
future studies.  
 
In addition to study PMVs exposing CD62P, we also studied PMVs exposing CD40L 
(CD145+), which is a cytokine belonging to the TNF superfamily and secreted from and 
exposed on activated platelets. We have previously found that CD40L can be detected on 
PMVs with high sensitivity (126).The data obtained on CD40L positive PMVs showed a 
similar trend as the data observed with the other PMV phenotypes, but PMVs exposing 
CD40L were detected at much lower concentrations than the other PMV phenotypes 
investigated.  
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Although our data on PMVs show significant relationships to clopidogrel responsiveness 
and ADP-induced aggregability, indicating that ADP and inhibition of its effects are 
mechanistically important, the generation of PMVs in the circulation of CAD patients is 
likely dependent also on many other mechanisms than those related to ADP. PMVs data 
obtained in ACS patients should therefore – in our opinion – more be viewed upon as 
reflecting “global platelet activation” in vivo.  
 
 
5.3 Study III 
 
As described in the introduction of the present thesis, MVs may deliver biological effects. 
For example, MVs have strong pro-coagulant effects and boost thrombin generation, 
mainly through the exposure of PS (88, 127). However, if MVs interact with and influence 
platelet aggregation had been little investigated when this thesis started, at least in the 
setting of ACS. After our findings made in study II, where we observed an association 
between MVs, and ADP induced platelet aggregability and clopidogrel responsiveness, we 
hypothesized that MVs could enhance platelet aggregation, and perhaps contribute to HPR 
to clopidogrel. In order to study the effects of MVs on platelets, we searched for a method 
with which we could study platelet aggregation in vitro, and that could be carried out in 
samples with small volumes. Notably, our simple method to enrich MVs from plasma was 
based on centrifugation and yielded only small volumes of MVs. The method described by 
Armstrong et. al (118), which uses 96-well microplates to study platelet aggregation (changes 
in absorbance when platelets aggregate) turned out to be useful. When adding MVs from 
ACS patients with HPR to clopidogrel, to PRP from a healthy subject, we could 
demonstrate enhanced platelet aggregation compared to if MVs from patients with LPR 
were added to the same PRP. The MVs from patients with poor responsiveness to 
clopidogrel (HPR) thus had a pro-aggregatory effect which MVs from the clopidogrel 
responders (Non-HPR) lacked. There were significant correlations in plasma between PMV 
concentrations as assessed by FCM and the pro-aggregatory effects that the MV suspension 
caused in the wells, which further supported our idea that MVs from HPR patients may 
contribute to increased platelet aggregability and perhaps partly explain the phenomenon of 
HPR. Notably, similar data were obtained when we compared MVs from patients to 
diabetes mellitus – a condition associated with platelet hyperreactivity and increased levels 
of MVs – to MVs from patients without diabetes: MVs from diabetes patients had a 
significantly stronger pro-aggregatory effect irrespective of clopidogrel responsiveness.  
 
Our experiments in study III may be viewed upon as a bit simple and incomplete, as we 
have not studied the enhancing effects of MVs on agonist induced platelet aggregation, e.g. 
on ADP, AA or TRAP induced platelet aggregation. This will require more experiments, 
likely with subthreshold concentrations of agonists, as enhancing effects is easier to reveal 
at the lower parts of the dose-response curve. But as pointed out by Bampalis et al in their 
methodological study of MEA and spontaneous platelet aggregation in whole blood, the 
tendency of spontaneous platelet aggregation leads to an increase of stimulated platelet 
aggregation values (128), so it may be that HPR as detected by MEA is partly due to the 
presence of pro-aggregatory MVs in the sample.  
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Based on our data it is tempting to speculate that generation of pro-aggregatory MVs from 
activated platelets may enhance platelet aggregation and increase the risk of platelet 
dependent thrombus-formation, e.g. at the location of an implanted coronary stent or plaque 
rupture. This scenario could mechanistically, at least partly, explain why HPR patients are 
at higher risk of a recurrent vascular complication.  
 
 
5.4 Study IV 
 
In study IV we wanted to take our FCM MV method further and assess if MVs expose an 
inflammatory biomarker with rapid dynamics which potentially could reflect 
atherosclerosis, plaque vulnerability and rupture, i.e. the long pentraxin molecule PTX3, 
see e.g. (129). To our knowledge, we are the first to demonstrate the exposure and dynamics 
of PTX3 on MVs in ACS. We found substantially elevated circulating plasma levels of 
PTX3+-MVs in the acute phase of STEMI before PCI and with a significant reduction after 
PCI. Sampling from NSTEMI patients at discharge 3-5 days after admission, showed even 
lower PTX3+-MV levels but they were not as low as in healthy subjects. We also used a 
conventional ELISA developed to measure plasma PTX3, and could confirm that a 
significant amount of the soluble PTX3 circulating in plasma is found on MVs. Although 
the MV bound portion may be comparatively small, it can be sensitively detected with our 
FCM method. In fact, this method is an attractive alternative to ELISAs, and may even be a 
better method to detect dynamic changes in biologically active molecules in response to 
various inflammatory conditions, as described by us previously for CD40L (126), and 
perhaps also for HMBG1(130), Notably, in these two latter studies we phenotyped the MVs 
and could detect that they carried molecules of platelet, and monocyte origins, respectively, 
indicating that the MVs were released from these cell types. In this context, it is important 
to put forward the possibility that some of the PTX3+-MVs that we measure may be of 
platelet origin, as PTX3 is known to bind to P-selectin on activated platelets (106). 
 
Furthermore, a future challenge will be to try to determine the cellular sources of MVs 
exposing PTX3. It is possible to assess if circulating PTX3+-MVs carry antigens 
suggesting neutrophil origin (e.g. CD66b or Myeloperoxidase [MPO]) or vascular 
endothelial cell antigens such as E-selectin or CD144. Such data could add information on 
the source and pathophysiology of PTX3 in AMI. 
 
 
5.5 Concluding remarks and future perspective 
 
Management of thrombotic and bleeding complications is a growing challenge for health 
care, as the number of patients who need antithrombotic treatment is increasing. In fact, 
nowadays the antithrombotic treatment strategy may include drug combinations with the 
aim to inhibit both platelet function and coagulation. In the treatment of ACS, interventions 
with PCI in combination with DAT has become “standard of care” worldwide. The use of 
the novel P2Y12 inhibitors prasugrel and ticagrelor has increased, but clopidogrel is still a 
commonly used P2Y12 inhibitor, and perhaps even still the most used one worldwide (39, 40) . 
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However, interindividual variability to antiplatelet treatment, especially clopidogrel, is a 
problem as poor responsiveness to clopidogrel treatment is associated with increased risk of 
major cardiovascular events, including stent thrombosis. The idea that platelet function 
testing with POC devices in this context may be of value continues to be under 
investigation (131). Some large RCTs have been negative in this respect, see e.g. (132-134), but 
a recent study with a different approach, opens up for different strategies how to use POC 
assay to guide antiplatelet treatment (135). As indicated by yet another clinical trial, it may be 
that we use strong platelet inhibiting treatment in a too aggressive way, and that  
de-escalation in antiplatelet efficiency after the first month phase following ACS can be an 
alternative approach (136). The implementation of an individualized approach according  
to a “therapeutic interval” regarding ADP-response to DAT as has been previously 
proposed (14, 137) , is in my mind a tempting approach but further studies on the matter have 
to be performed (131) before such an approach can be implemented in clinical routine.  
The field of MVs and its role as “markers and makers” of various diseases is rapidly 
expanding. MVs, and especially PMVs, are more abundant in the circulation of “poor 
responders” to clopidogrel, according to this thesis. We could also demonstrate that MVs 
from “clopidogrel poor-responders” enhance platelet aggregation, and that this 
phenomenon also is seen with MVs from ACS patients with diabetes mellitus. However, 
these data were obtained in a pilot study and more studies are needed to understand this 
phenomenon in more detail. For example, how MVs influence platelet aggregation to 
various agonists have to be studied in proper experiments with full dose-response curves for 
the respective agonists (as alluded to above enhancing effects are likely to be more easily 
demonstrated at the lower part of dose-response curves). The “Armstrong method” should 
be a sufficient method for this purpose. Furthermore, MVs obtained from patients on 
ticagrelor or prasugrel should be investigated with respect to pro-aggregatory properties; 
these are also studies that easily can be performed.  
 
The cellular origin of circulating MVs exposing PTX3 is another topic which should be 
explored in the future in patients with ACS, but this issue could also be further investigated 
in experimental models of inflammation, such as the endotoxin model, previously used by 
us (126, 130, 138). Another aspect which deserves studying is pre-analytical handling and 
comparisons of arterial and venous sampling for measurement of MVs in the setting of 
ACS, similar to the experiments carried out in study I for MEA. Indeed, our idea to assess 
sample quality through the use of phalloidin exposure as described by us (73), and used by 
others (139) could be adapted in these studies.  
 
Lastly, but most challenging, large studies to investigate the usefulness of MVs in terms of 
prognosis should be performed. To our knowledge, such studies are few or lacking in 
coronary artery disease (140).  
 
 
 
 
 
 
  36 
6 CONCLUSIONS 
 
Ø   Both arterial and venous blood samples can be used in the detection of high on treatment 
platelet reactivity (HPR) to dual antiplatelet treatment with aspirin and clopidogrel, when 
platelet aggregation is studied with multiple electrode aggregometry (MEA).  
 
Ø   Patients with an acute coronary syndrome and HPR to clopidogrel, have elevated levels 
of circulating microvesicles (MVs) and platelet microvesicles (PMVs), which indicate 
ongoing platelet activation. 
 
Ø   Circulating MVs from ACS patients with HPR to clopidogrel are able to enhance platelet 
aggregation. 
 
Ø   Circulating pentraxin-3 (PTX3) is partially bound to MVs, and elevated in patients with 
acute myocardial infarction. The plasma levels of MVs exposing PTX3 decline over the 
first days following the infarction, likely reflecting the effects of treatment and the natural 
course of the disease. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Bakgrund 
 
Akuta koronara syndrom (AKS), ett samlingsnamn för akut hjärtinfarkt och svår (instabil) 
kärlkramp, är en mycket vanlig dödsorsak i den vuxna befolkningen. Tillståndet beror på 
åderförfettning (ateroskleros) i hjärtats kranskärl. Aterosklerosen skapar förträngningar 
vilka hindrar blodflödet ut i hjärtmuskeln med risk för syrebrist och kärlkramp. I vissa 
kärlområden kan aterosklerosen bilda särskilt svåra förträngningar, s.k plack. Dessa 
aterosklerotiska plack kan brista och på platsen för brustna plack bildas blodproppar som 
riskerar helt täppa igen kranskärlen. Detta kan leda till total syrebrist och död av delar av 
hjärtmuskeln, en hjärtinfarkt har uppkommit. Blodproppsbildningen beror till stor del på att 
trombocyter (blodplättar) i blodet bildar proppar på platsen för plackrupturen.  
 
En av hörnstenarna i behandling av AKS är medicinering med trombocythämmande 
läkemedel i kombination med ballongvidgning av förträngningarna (s.k. PCI). Vid PCI 
läggs ofta ett nät, s.k stent, in i kärlet för att stabilisera kärlvidgningen. Denna åtgärd ökar 
emellertid risken för ny blodproppsbildning vilket i sin tur ökar behovet av 
trombocythämmande läkemedel, och för optimalt skydd mot ny propp måste två olika 
läkemedel ges, acetylsalicylsyra (ASA) och clopidogrel. För clopidogrel varierar den 
trombocythämmande effekten mellan olika individer, och det är visat att individer med 
mindre hämmande effekt har ökad risk att få ny blodpropp och hjärtinfarkt, särskilt på 
platsen för stentinläggning.  
 
Det finns idag olika metoder (blodprov) som mäter den blodproppshämmande effekten av 
clopidogrel, och det är visat att individer med mindre hämmande effekt av clopidogrel har 
ökad risk för blodpropp i kranskärlen. Det är emellertid inte vetenskapligt säkerställt att 
rutinmässig användning av sådana metoder, och justering av trombocythämmande medel 
(val av andra läkemedel) utifrån testresultaten, leder till minskat återinsjuknande i 
hjärtinfarkt och död.      
 
 
Frågeställningar 
 
Föreliggande avhandling har därför undersökt etablerade samt nya metoder för att mäta 
blodproppsbildning hos trombocyter vid AKS. Vi har undersökt en kommersiellt tillgänglig 
metod som mäter blodproppsbildning i ett blodprov, s.k helblodsaggregometri (MEA),  
och om blodprover tagna direkt från kranskärlen i samband med ballongvidgningen ger 
samma testresultat som de blodprover som tas från en vanlig provtagning i en ven på armen 
(studie 1). Metoden MEA har jämförts med en annan metod som mäter små partiklar som 
knoppas av från trombocyter i blodet (s.k. mikrovesiklar [MV], studie 2), och vi har 
undersökt om dessa MV påverkar trombocyters benägenhet att bilda proppar (studie 3). 
Slutligen har vi undersökt om MV bär ett protein som visats frisättas i blodet vid 
hjärtinfarkt, och som kan vara av inblandat i mekanismer relevanta för hjärtinfarkt  
(studie 4).  
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Resultat och slutsatser 
 
I studie 1 undersöktes 28 kranskärlssjuka patienter som genomgick PCI, och alla 
behandlades med ASA och clopidogrel. Effekten av behandlingen jämfördes i arteriellt 
blod (taget direkt ifrån kranskärlen vid PCI) och venöst blod taget på rutinmässigt sätt  
från en ven i armvecket. Blodproverna analyserades med hjälp av metoden MEA,  
och vi jämförde resultaten från de två provtagningstyperna.  
Vi fann en god överensstämmelse mellan de två olika typerna av provtagning vad  
gäller att diagnosticera om patienter uppvisade god eller bristfällig hämning av  
clopidogrel-behandlingen. Fyndet är viktigt då det ibland är det svårt att få tillgång  
till det rutinmässiga venösa blodprovet i det brådskande akuta skedet. Man kan i  
enlighet med vår studie, sålunda använda både prover tagna från kranskärlen och 
blodprover tagna från en ven i armen. 
 
I studie 2 undersöktes 183 patienter med AKS och trombocyters proppbildning 
(aggregation) undersöktes med hjälp av MEA. Vi fann att ca 20% av patienterna  
svarade bristfälligt på clopidogrel (s.k. ”non-responders”) vilket överensstämmer med 
tidigare studier. Vi undersökte vidare förekomsten av s.k. mikrovesiklar med en metod  
som utvecklats på vårt laboratorium. MV utsöndras främst från trombocyter men kan  
även frisättas från andra celler, t ex från vita blodkroppar eller från kärlväggens celler.  
Vi fann att patienter med god effekt av clopidogrel hade lägre nivåer av MV i blodet, 
särskilt MV från trombocyter. Dessutom fann vi att de patienter som hade mycket god 
trombocythämmande effekt av clopidogrel hade lägst antal trombocyt-MV i blodet. 
Metoden som mäter antal trombocyt-MV i blodet skulle kunna användas för att hitta 
patienter med risk för blodproppskomplikationer. Dessutom uppkom nu frågan om de 
trombocyt-MV som vi hittar i blodet hos AKS-patienter kan påverka trombocyters 
benägenhet till proppbildning (trombocyt-aggregation).  
 
I studie 3 undersöktes den frågeställning som uppkommit som resultat av studie 2,  
dvs om MV i blodet påverkar trombocyters tendens till proppbildning (aggregation).  
Vi renade fram MV från patienter med god respektive bristfällig trombocythämmande 
effekt av clopidogrel. Dessa MV tillsattes till trombocytrik plasma från friska individer. 
Trombocytaggregation undersöktes med en metod som kräver relativt små volymer prov. 
Vi fann att MV från patienter med bristande hämning av clopidogrel förstärkte 
trombocyters aggregation, talande för att hos dessa individer finns MV som kan medverka 
till ökad blodproppsbildning. Idén att MV i blodet påverkar trombocytaggregation stöddes 
också av fynd som visade att MV från AKS patienter med diabetes, ett tillstånd med ökad 
trombocytaggregation, också förstärkte trombocytaggregation jämfört med MV från AKS 
patienter utan diabetes. Sammanfattningsvis finner vi i studie 3 stöd för att MV i blodet  
kan förstärka trombocyters tendens att bilda blodpropp (aggregera), särskilt hos patienter 
med bristande effekt av clopidogrel, och hos patienter med diabetes.     
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I studie 4 undersökte vi om MV från patienter med akut hjärtinfarkt bär på ett protein  
som påverkar inflammation och blodproppsbildning. Proteinet (pentraxin-3) har i andra 
studier visats relatera till sämre prognos efter hjärtinfarkt. Vi kunde finna att vid det  
akuta insjuknandet i hjärtinfarkt cirkulerar MV som bär på pentraxin-3, och nivåerna 
sjunker efter PCI, och är ytterligare lägre i samband med hemskrivning från 
hjärtinfarktavdelningen. Nivåerna når dock ej de låga nivåer i blodet som uppmäts hos 
friska individer. Cellursprunget av pentraxin-3 kan identifieras med vår metod i framtida 
studier, genom att samtidigt mäta cellspecifika molekyler på ytan av de MV som bär 
pentraxin-3. På detta sätt kan vi förstå var pentraxin-3 bildas och dess roll i 
sjukdomsprocessen vid hjärtinfarkt.   
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